The brains of patients suffering from Alzheimer’s disease comprise very high levels of BuChe, hence several anti-Alzheimer’s drugs target the cholinergic neurons, including BuChe inhibitors, and promote the expression of ChAT, thereby producing protective effects by stimulating nerve growth factors and brain derived neurotrophic factors and their receptors. Here, BDNF is linked to early-onset autosomal dominant Alzheimer disease.